Cybin (OTCMKTS:CYBN) Trading Up 0.2% - Here's What Happened

Cybin Inc. (OTCMKTS:CYBN - Get Free Report) shot up 0.2% on Tuesday . The company traded as high as $10.18 and last traded at $10.14. 57,400 shares traded hands during trading, a decline of 60% from the average session volume of 142,240 shares. The stock had previously closed at $10.12.

Cybin Stock Performance

The company has a fifty day simple moving average of $6.79 and a two-hundred day simple moving average of $2.59. The firm has a market capitalization of $198.72 million, a PE ratio of -1.64 and a beta of 0.38.

Cybin (OTCMKTS:CYBN - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.01) earnings per share for the quarter. On average, equities analysts anticipate that Cybin Inc. will post -0.19 earnings per share for the current fiscal year.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.